Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
NCT06951854Phase 2Recruiting
- Sponsor
- NeuroVenti
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NV01-A02 in Autism Spectrum Disorder (ASD), sponsored by NeuroVenti. Started Apr 2025; status: recruiting.
02
Drugs
NV01-A02
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06951854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951854.